Zentalis Pharmaceuticals Inc Ordinary Shares ZNTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $10.99
- Day Range
- $10.77–11.23
- 52-Week Range
- $9.56–31.46
- Bid/Ask
- $10.09 / $11.16
- Market Cap
- $784.82 Mil
- Volume/Avg
- 474,113 / 829,308
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 168
- Website
- https://www.zentalis.com
Comparables
Valuation
|
Metric
|
ZNTL
|
CLDX
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.79 | 4.73 | 3.18 |
Price/Sales | — | 255.51 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ZNTL
CLDX
TYRA
Financial Strength
|
Metric
|
ZNTL
|
CLDX
|
TYRA
|
|---|---|---|---|
Quick Ratio | 6.96 | 13.69 | 13.27 |
Current Ratio | 7.16 | 13.87 | 13.80 |
Interest Coverage | — | — | — |
Quick Ratio
ZNTL
CLDX
TYRA
Profitability
|
Metric
|
ZNTL
|
CLDX
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −33.50% | −30.49% | −22.50% |
Return on Equity (Normalized) | −41.29% | −33.19% | −23.73% |
Return on Invested Capital (Normalized) | −37.58% | −32.85% | −27.79% |
Return on Assets
ZNTL
CLDX
TYRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qclgfkdjqw | Sjhkv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bzpbfcqc | Vvhvdbd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jppnqlpv | Hvwsz | $97.8 Bil | |
MRNA
| Moderna Inc | Kfmbtdyy | Dglmm | $41.3 Bil | |
ARGX
| argenx SE ADR | Hcxpxvzxb | Xbqfr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hhkxsyc | Wftt | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gzfrwzysq | Kgswpx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rrrxhvkf | Mwmkbpd | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gmgkpjjfz | Kljgy | $12.5 Bil | |
INCY
| Incyte Corp | Zthckbdq | Xdqwfs | $11.6 Bil |